Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma

Next Previous
Trial Profile

A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Penpulimab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Akeso Biopharma

    • Most Recent Events

    • 02 Apr 2024 Status changed from recruiting to completed.
    • 07 Jun 2022 Results of a pooled analysis (NCT03722147, NCT03209973, NCT03155425 and NCT03655483) assessing the survival outcome of patients with relapsed or refractory classical Hodgkin lymphoma who achieved remission during immune checkpoint inhibitors treatment presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 05 Aug 2021 According to Akeso media release, Penpulimab has obtained marketing approval by the National Medical Products Administration of China, for treatment of patients with relapsed or refractory classic Hodgkins lymphoma after at least second-line systemic chemotherapy treatment based on this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top